Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Journal of the American Heart Association|April 21, 2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y<sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC StudyFrancesco Franchi, Fabiana Rollini, Gabriel Faz, et al.
Journal of the American Heart Association|June 14, 2024
<i>CYP2C19</i> Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary InterventionKayla R Tunehag, Cameron D Thomas, Francesco Franchi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 TrialConnie N Hess, Judith Hsia, Ian A Carroll, et al.
Circulation|November 1, 2017
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting TherapiesDominick J Angiolillo, Fabiana Rollini, Robert F Storey, et al.
Clinical Pharmacology and Therapeutics|October 28, 2022
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y<sub>12</sub> Inhibitor Prescribing After Percutaneous Coronary InterventionLarisa H Cavallari, Nita A Limdi, Amber L Beitelshees, et al.
Clinical and Translational Science|August 16, 2024
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategiesLarisa H Cavallari, Craig R Lee, Francesco Franchi, et al.
Clinical Pharmacology and Therapeutics|April 16, 2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World InvestigationCameron D Thomas, Francesco Franchi, Ellen C Keeley, et al.
Journal of the American College of Cardiology|April 10, 2024
Effectiveness of Clopidogrel vs Alternative P2Y<sub>12</sub> Inhibitors Based on the ABCD-GENE ScoreCameron D Thomas, Francesco Franchi, Joseph S Rossi, et al.
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
Research Square|September 2, 2025
Persistent Tic Disorders Are Associated With 17q12 DuplicationsMatthew Halvorsen, Sheng Wang, Tyne Miller-Fleming, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Journal of the American Heart Association|April 21, 2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y<sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC StudyFrancesco Franchi, Fabiana Rollini, Gabriel Faz, et al.
Journal of the American Heart Association|June 14, 2024
<i>CYP2C19</i> Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary InterventionKayla R Tunehag, Cameron D Thomas, Francesco Franchi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 TrialConnie N Hess, Judith Hsia, Ian A Carroll, et al.
Circulation|November 1, 2017
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting TherapiesDominick J Angiolillo, Fabiana Rollini, Robert F Storey, et al.
Clinical Pharmacology and Therapeutics|October 28, 2022
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y<sub>12</sub> Inhibitor Prescribing After Percutaneous Coronary InterventionLarisa H Cavallari, Nita A Limdi, Amber L Beitelshees, et al.
Clinical and Translational Science|August 16, 2024
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategiesLarisa H Cavallari, Craig R Lee, Francesco Franchi, et al.
Clinical Pharmacology and Therapeutics|April 16, 2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World InvestigationCameron D Thomas, Francesco Franchi, Ellen C Keeley, et al.
Journal of the American College of Cardiology|April 10, 2024
Effectiveness of Clopidogrel vs Alternative P2Y<sub>12</sub> Inhibitors Based on the ABCD-GENE ScoreCameron D Thomas, Francesco Franchi, Joseph S Rossi, et al.
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
Research Square|September 2, 2025
Persistent Tic Disorders Are Associated With 17q12 DuplicationsMatthew Halvorsen, Sheng Wang, Tyne Miller-Fleming, et al.
Pageof 15